ImmuPharma plc (LON:IMM – Get Free Report)’s share price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of GBX 3.64 and traded as low as GBX 3.10. ImmuPharma shares last traded at GBX 3.21, with a volume of 2,801,252 shares changing hands.
ImmuPharma Stock Down 17.8%
The company has a 50 day moving average of GBX 3.64 and a 200 day moving average of GBX 4.75. The stock has a market capitalization of £20.04 million, a price-to-earnings ratio of -3.86 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 559.87% and a net margin of 3,519.56%. On average, research analysts forecast that ImmuPharma plc will post -339.00 earnings per share for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
- LyondellBasell’s Dividend Looks Safer, But a New Risk Could Change That
- L3Harris Stock Took a Beating—Is a 20% Rebound Next?
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
